Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Laszlo D, et al. Among authors: calabrese l. J Clin Oncol. 2010 May 1;28(13):2233-8. doi: 10.1200/JCO.2009.23.6315. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368573 Clinical Trial.
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.
Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G. Bertazzoni P, et al. Among authors: calabrese l. Leuk Lymphoma. 2010 Aug;51(8):1485-93. doi: 10.3109/10428194.2010.495799. Leuk Lymphoma. 2010. PMID: 20578816
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Martinelli G, et al. Among authors: calabrese l. J Clin Oncol. 2005 Mar 20;23(9):1979-83. doi: 10.1200/JCO.2005.08.128. Epub 2005 Jan 24. J Clin Oncol. 2005. PMID: 15668468 Clinical Trial.
Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected].
Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, Pruneri G, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H. Martinelli G, et al. Among authors: calabrese l. Leuk Lymphoma. 2009 Jun;50(6):925-31. doi: 10.1080/10428190902912478. Leuk Lymphoma. 2009. PMID: 19479614 Clinical Trial.
Weekly epirubicin in the treatment of gestational breast cancer (GBC).
Peccatori FA, Azim HA Jr, Scarfone G, Gadducci A, Bonazzi C, Gentilini O, Galimberti V, Intra M, Locatelli M, Acaia B, Rossi P, Cinieri S, Calabrese L, Goldhirsch A. Peccatori FA, et al. Among authors: calabrese l. Breast Cancer Res Treat. 2009 Jun;115(3):591-4. doi: 10.1007/s10549-008-0159-2. Epub 2008 Aug 20. Breast Cancer Res Treat. 2009. PMID: 18712595
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. Pruneri G, et al. Among authors: calabrese l. Leuk Res. 2008 Oct;32(10):1628-32. doi: 10.1016/j.leukres.2008.02.002. Epub 2008 Mar 19. Leuk Res. 2008. PMID: 18355918 No abstract available.
The clinical assessment of lung involvement in patients with Still's disease, results from the multicentre international AIDA Network Still's Disease Registry.
Ruscitti P, Vitale A, Di Cola I, Caggiano V, Palumbo P, Di Cesare E, Hinojosa-Azaola A, Torres-Ruiz J, Guaracha-Basañez GA, Martín-Nares E, Lopalco G, Morrone M, Iannone F, Giardini HAM, Cordeiro RA, de Brito Antonelli IP, Berardicurti O, Navarini L, Ciccia F, Visconti MC, Iacono D, Direskeneli H, Erten S, Yao H, Thabet M, Tharwat S, Ragab G, Gómez-Caverzaschi V, Sfikakis PP, Fotis L, La Torre F, Maier A, Karamanakos A, Almaghlouth IA, Frassi M, Tufan A, Govoni M, Sota J, Simonini G, Emmi G, Li Gobbi F, Parronchi P, Costi S, Sarzi-Puttini P, Opris-Belinski D, Sfriso P, Tarsia M, Maggio MC, Monti S, Gündüz ÖS, Rigante D, Bartoloni E, Verrecchia E, Iagnocco A, Viapiana O, Bargagli E, Batu ED, Sebastiani GD, Del Giudice E, Conti G, Breda L, Gidaro A, Gicchino MF, Gaggiano C, Brucato AL, Triggianese P, Makowska J, Carubbi F, Farina N, Guggino G, De Paulis A, Mazzei MA, Di Meglio N, Lo Gullo A, Conforti A, Ogunjimi B, Calabrese L, Rubegni P, Giardina A, Wiesik-Szewczyk E, Balistreri A, Fabiani C, Frediani B, Dagna L, Giacomelli R, Cantarini L. Ruscitti P, et al. Among authors: calabrese l. Rheumatology (Oxford). 2025 Jan 20:keaf021. doi: 10.1093/rheumatology/keaf021. Online ahead of print. Rheumatology (Oxford). 2025. PMID: 39832276
781 results